Abstract
Introduction/Objective. Isocitrate dehydrogenase mutations play a significant role in gliomagenesis. Specific microRNAs such as miR-10b/21 act as oncogenic microRNAs, while miR-34a acts as tumor suppressors in glioblastoma. Our study aimed to investigate the mutation status of IDH correlate with microRNAs-10b/21/34a expression levels in patients with glioblastoma. Methods. The study included 43 patients diagnosed with glioblastoma. We examined microRNA-10b, microRNA-21 and microRNA-34a expression levels in peripheral blood mononuclear cells after surgery and prior to concurrent radiotherapy with temozolomide, at the 15th and 30th fractions of radiotherapy with temozolomide. The data on IDH1 mutation status were gathered from medical history and histopathology. Results. Two groups were created to assess the association of microRNAs-10b/21/34a expression levels: glio-blastoma IDH1-wild type and glioblastoma IDH1-mutant + Not Other Specified (NOS). The median microRNA-10b expression level before the initiation of concurrent radiotherapy with temozolomide was 130.44 (52.20 - 622.53) in the IDH1-wildtype glioblastoma group and 94.61 (2.13 - 816.89) in the IDH1-mutant + glioblastoma NOS group. The median microRNA-21 expression level was 57.16 (2.68 - 278.98) in the IDH1-wildtype glioblastoma group and 69.74 (4.60 - 825.43) in the IDH1-mutant + glioblastoma NOS group. The median microRNA-34a expression level was 13.52 (3.16 - 105.20) in the IDH1-wildtype glioblastoma group and 10.11 (1.00 - 210.55) in the IDH1-mutant + glioblastoma NOS group. The results showed no statistically significant difference in the expression levels of miR-10b/21/34a between the two groups (p > 0.05). Conclusion. Our results suggest that the IDH1 mutation status may not be a critical factor for altered expression of microRNAs-10b/21/34a in glioblastoma patients.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call